DEPAKOTE ER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEPAKOTE ER (DEPAKOTE ER).
Increases GABAergic activity by inhibiting GABA transaminase and succinate semialdehyde dehydrogenase; blocks voltage-gated sodium and T-type calcium channels; reduces glutamate release.
| Metabolism | Primarily hepatic via glucuronidation (30-50%), β-oxidation (40%), and cytochrome P450 (CYP) systems including CYP2C9, CYP2A6, CYP2B6, CYP2C19, and CYP3A4; not significantly metabolized via CYP2D6. |
| Excretion | Primarily renal (30-50% as glucuronide conjugates, <3% as unchanged drug); minor fecal (10-20%) |
| Half-life | Terminal elimination half-life is approximately 20 hours (range 10-60 hours); clinical context: extended-release formulation allows once-daily dosing, steady-state achieved in 4-5 days |
| Protein binding | 90-95% bound, primarily to albumin; binding saturable at higher concentrations (free fraction increases above 100 mcg/mL) |
| Volume of Distribution | 0.13-0.24 L/kg; clinical meaning: low Vd indicates primarily extracellular distribution, limited tissue penetration except in brain and liver |
| Bioavailability | Extended-release oral: approximately 90% relative to intravenous; absolute bioavailability ~100% for immediate-release; food does not affect extent but may decrease peak concentration |
| Onset of Action | Extended-release oral: onset of therapeutic effect typically within 1-3 days for acute mania; may take 1-2 weeks for full antiepileptic effect |
| Duration of Action | Approximately 24 hours for once-daily dosing; clinical notes: therapeutic levels maintained throughout dosing interval due to extended-release formulation |
500-1000 mg orally once daily; usual maximum dose 60 mg/kg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No specific dose adjustment recommended; monitor for adverse effects in severe renal impairment (CrCl <10 mL/min). |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in mild-to-moderate impairment (Child-Pugh class A or B) with reduced initial dose and monitoring of liver function. |
| Pediatric use | Initial 10-15 mg/kg/day in 1-2 divided doses; increase by 5-10 mg/kg/day weekly to clinical response; typical dose 20-60 mg/kg/day. |
| Geriatric use | Initiate at lower doses (125-250 mg once daily) and titrate slowly; monitor for confusion, sedation, and tremor; reduce dose if concomitant antiepileptic drugs or renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEPAKOTE ER (DEPAKOTE ER).
| Breastfeeding | Excreted in breast milk. M/P ratio approximately 0.1-0.5. Infant serum levels 1-10% of maternal. Monitor infant for thrombocytopenia, hepatotoxicity, sedation. Generally considered compatible but caution advised. |
| Teratogenic Risk | Highest risk in first trimester for neural tube defects (3-5% absolute risk), facial clefts, cardiac malformations, hypospadias. Second and third trimester: neurodevelopmental delay, autism spectrum disorders, reduced IQ. Late pregnancy: neonatal hemorrhage, hepatotoxicity, hypoglycemia. |
■ FDA Black Box Warning
Hepatotoxicity, teratogenicity (including neural tube defects such as spina bifida), pancreatitis, and life-threatening adverse reactions in patients with mitochondrial disease (particularly those with polymerase gamma [POLG] mutations).
| Serious Effects |
Known hypersensitivity to valproate; hepatic disease or significant hepatic dysfunction; urea cycle disorders; known mitochondrial disorders caused by POLG mutations (especially in children <2 years); use in pregnancy for migraine prophylaxis (Category X).
| Precautions | Monitor liver function tests and platelet counts; may cause hyperammonemia, thrombocytopenia, pancreatitis, and multi-organ hypersensitivity reactions; use caution in patients with hepatic disease, mitochondrial disorders, or concomitant medications affecting coagulation; avoid abrupt discontinuation to prevent seizure exacerbation. |
| Food/Dietary | Depakote ER should be taken with food to minimize gastrointestinal irritation. There are no specific dietary restrictions; however, avoid grapefruit and grapefruit juice as they may affect drug metabolism. High-fat meals may delay absorption but do not significantly alter overall exposure. Ensure adequate fluid intake to prevent dehydration, which can increase risk of hyperammonemia. |
Loading safety data…
| Fetal Monitoring |
| Preconception: folate supplementation 5 mg/day. First trimester: targeted ultrasound for neural tube defects and fetal echocardiography at 18-22 weeks. Throughout pregnancy: serum valproate levels monthly, CBC, LFTs, coagulation profile. Third trimester: fetal monitoring for growth restriction. Postpartum: neonatal vitamin K, assess for bleeding and hypoglycemia. |
| Fertility Effects | May cause reversible menstrual irregularities, anovulation, polycystic ovarian syndrome (PCOS) in women of childbearing age. No direct effect on sperm parameters in men, but possible hormonal alterations. |
| Clinical Pearls | Depakote ER (divalproex sodium extended-release) is FDA-approved for migraine prophylaxis, bipolar mania, and epilepsy (complex partial, absence, and tonic-clonic seizures). Therapeutic drug monitoring of valproic acid total serum concentration is recommended (target 50-100 mcg/mL for epilepsy; for bipolar, lower end of range may suffice). ER formulation reduces peak-to-trough fluctuations compared to delayed-release, potentially improving tolerability. Caution in hepatic disease: LFTs and ammonia must be monitored. Hyperammonemic encephalopathy can occur even with normal LFTs. Valproate is a known teratogen (neural tube defects); avoid in pregnancy unless absolutely necessary. Pancreatitis is a rare but serious adverse effect; educate patients to report abdominal pain, nausea, vomiting. Drug interactions: valproate inhibits CYP2C9 and glucuronidation; levels of lamotrigine, phenobarbital, and tricyclic antidepressants can increase. Concomitant use with topiramate or acetazolamide increases risk of hyperammonemia. In elderly, start low and titrate slowly due to altered pharmacokinetics. Platelet dysfunction and thrombocytopenia can occur; monitor CBC with platelets periodically. |
| Patient Advice | Take Depakote ER once daily with food to reduce stomach upset. Swallow tablet whole; do not crush or chew. · Do not stop taking this medication abruptly without consulting your doctor, as this may cause seizures or mood worsening. · Regular blood tests are required to monitor liver function, blood counts, and medication levels. · If you experience severe abdominal pain, nausea, or vomiting, seek medical attention immediately as this may be a sign of pancreatitis. · Valproate can cause birth defects; use effective contraception and notify your doctor if you become pregnant or plan to become pregnant. · Avoid alcohol while taking this medication as it can increase side effects like drowsiness and liver damage. · Drowsiness or dizziness may occur; avoid driving or operating machinery until you know how this medication affects you. |